Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial-Reference-Cited by-同舟云学术

Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial

Published:2019-09-27 Issue:2 Volume:125 Page:226-233
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Allott Emma H.¹²^ORCID,Csizmadi Ilona³,Howard Lauren E.⁴,Muller Roberto L.⁵,Moreira Daniel M.⁶,Andriole Gerald L.⁷,Roehrborn Claus G.⁸,Freedland Stephen J.³⁹^ORCID

Affiliation:

1. Centre for Cancer Research and Cell Biology; Queen's University Belfast; Belfast UK

2. Department of Histopathology and Morbid Anatomy; Trinity Translational Medicine Institute; Trinity College Dublin; Dublin Ireland

3. Department of Surgery; Division of Urology; Cedars-Sinai Medical Center; Los Angeles CA USA

4. Duke Cancer Institute; Duke University School of Medicine; Durham NC USA

5. Division of Urology; Center of Oncologic Research (CEPON); Florianopolis Santa Catarina Brazil

6. Department of Urology; University of Illinois at Chicago; Chicago IL USA

7. Division of Urologic Surgery; Department of Surgery; Washington University School of Medicine; St. Louis MO USA

8. Department of Urology; UT Southwestern Medical Center; Dallas TX USA

9. Urology Section; Veterans Affairs Medical Center; Durham NC USA

Funder

Irish Cancer Society

National Institutes of Health

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.14905/fullpdf

Reference39 articles.

1. Benign prostate hyperplasia: a review of the year's progress from bench to clinic;Donnell;Curr Opin Urol,2011

2. Economic costs of benign prostatic hyperplasia in the private sector;Saigal;J Urol,2005

3. Benign prostatic hyperplasia: effects on quality of life and impact on treatment decisions;Garraway;Urology,1994

4. Definition of at-risk patients: baseline variables;Roehrborn;BJU Int,2006

5. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial;Schenk;Am J Epidemiol,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of autophagy in prostate cancer and prostatic diseases: a new therapeutic strategy;Prostate Cancer and Prostatic Diseases;2024-01-31

2. PaSTe. Blockade of the Lipid Phenotype of Prostate Cancer as Metabolic Therapy: A Theoretical Proposal;Current Medicinal Chemistry;2023-06-07

3. Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial;Journal of Urology;2022-02

4. Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer;Pharmaceuticals;2022-01-26

5. A prospective clinical and transcriptomic feasibility study of oral‐only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity;Cancer;2021-04-21